Associated Papers
Comprehensive resistance profiling of chronic myeloid leukaemia associated ABL1 variants against five tyrosine kinase inhibitors using prime editing.
Jung Y et al.
Nature Biomedical Engineering, 2025
Asciminib resistance of a new BCR::ABL1 p.I293_K294insSSLRD mutant detected in a Ph + ALL patient.
Cullot G et al.
Annals of Hematology, 2025
Discovery and characterization of novel potent BCR-ABL degraders by conjugating allosteric inhibitor.
Liu H et al.
European Journal of Medicinal Chemistry, 2022
Development of asciminib, a novel allosteric inhibitor of BCR-ABL1.
Réa D et al.
Critical Reviews in Oncology/hematology, 2022
Application of targeted next generation sequencing for the mutational profiling of patients with acute lymphoblastic leukemia.
Janic D et al.
Journal of Medical Biochemistry, 2020
Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients.
Soverini S et al.
Oncotarget, 2016
26980736 (PubMed )
Supplement: oncotarget-07-21982-s001.pdf
Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells.
Jiang X et al.
Journal of the National Cancer Institute, 2007
Select a paper to view details